Abstract:Several patients do not benefit from anti-cancer immunotherapies due to resistance for metabolic adaptation and fitness of tumor cells. Highly glycolytic tumor cells outcompete effector T cells for glucose in the tumor microenvironment (TME), impairing T cell function. High levels of lactate dehydrogenase (LDH) correlate with poor prognosis in cancer patients undergoing immunotherapies, inducing aberrant angiogenesis by activating HIF-1α and VEGF expression in endothelial cells (ECs), underscoring a biological interplay between tumor metabolism and neo-angiogenesis that can impact anti-tumor immunity. Main vasculature cells – ECs and pericytes (PCs) – may serve as antigen-presenting cells (APC), influencing T cell responses. While these findings point to a joint metabolic and immune regulation of the vasculature:T-cell crosstalk in the TME, we currently lack a precise understanding of the mechanisms linking tumor metabolism, aberrant angiogenesis, and anti-tumor T-cell responses, and how cell-based therapy may be influence by these factors. We have compared and contrasted vasculature and immune cells phenotypes by high-dimensional flow cytometry in established tumor models representing three major metabolic states by perturbing the two main cellular hubs for producing energy (aerobic glycolysis, by LDHA knock-down; oxidative phosphorylation, by depleting mitochondria as in Rho0 cells) compared to control tumors (NC). We functionally tested the impact of intratumor T cell recruitment according to these phenotypes, by adoptive cell transfer (ACT) therapy using T cells from donor mice immunized with matched-tumor injected i.v. in RAG2 KO mice bearing metabolically-defective tumor (KD or Rho0) and control tumor (NC) in contralateral mammary fat pad. We found that glycolysis-low tumors (LDH-A KD) show a better vasculature with reduced proportions of angiogenic activated PCs (cluster1: NG2+PDGFRbneg) and increased frequencies of "stabilizing" PCs (cluster 2: NG2negPDGFRb+, which counteract the formation of leaky vessels), compared to NC. However, KD tumors also display a reduction in MECA-79+ high endothelial venules. Moreover, LDHA-KD vs. NC tumors displayed ECs and cluster 2 PCs with greater expression of MHCI and decreased expression of FAS-L, and more EC expressing MHCII or PD-L1. In addition, the immune infiltrate of KD tumors is characterized by increased amounts of T effector cells and lower amounts of Gr1-low myeloid derived suppressor cells (MDSCs). The changes in vascularization phenotype have been confirmed in RAG2 KO mice bearing bilateral tumor variants model. ACT in these mice bearing bilateral 4T1-NC and -KD tumors resulted in greater biodistribution of T cells in the KD tumors, showing decreasing tumor growth. Vasculature features correspond to greater intratumor T-cell trafficking, indicating a mechanistic link between tumor glycolysis, aberrant angiogenesis, and T-cell exclusion. This would aim to elucidate the mechanisms through which these processes are connected for developing more efficacious T-cell-targeted therapies. Citation Format: Giorgia Colombo, Jee Hye Kang, Inna Serganova, Roberta Zappasodi. Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B049.

Effector T cells in poorly perfused tumor regions exhibit a distinct signature of augmented IFN response and reduced PD-1 expression

Effector T Cells under Hypoxia Have an Altered Transcriptome Similar to Tumor-Stressed T Cells Found in Non-Responsive Melanoma Patients

Enhancing tumor-infiltrating T cells with an exclusive fuel source

663 Media based on the metabolic composition of tumor interstitial fluid reveals persistent T cell dysfunction induced through arginine deprivation and exposure to the oncometabolite phosphoethanolamine

Abstract B049: Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity

Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth

Activation and antitumor immunity of CD8 + T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid

Suppression of T cell function by phosphoethanolamine, a metabolite enriched in tumor interstitial fluid

Enforcing GLUT3 expression in CD8+ T cells improves fitness and tumor control by promoting glucose uptake and energy storage

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

Circulating Clonally Expanded T Cells Reflect Functions of Tumor Infiltrating T Cells

Tumor infiltrating T cells have abnormal lipid metabolism that can be modulated by PD-L1 blockade.

A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

Tumor Aerobic Glycolysis Confers Immune Evasion Through Modulating Sensitivity to T Cell-Mediated Bystander Killing Via TNF-α.

Lipid metabolic features of T cells in the Tumor Microenvironment

Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells

Glut3 promotes cellular O -GlcNAcylation as a distinctive tumor-supportive feature in Treg cells

TFE3-SLC36A1 axis promotes resistance to glucose starvation in kidney cancer cells

Abstract A033: Pro-inflammatory tumor cells drive CD4+ T cell localization within heterogeneous tumors

Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment

High transferrin receptor expression marks tumors with increased immune-effector infiltration and expression of targetable checkpoint molecules: Results of a multi-cancer analysis in solid tumors.